Abstract
Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment for various hematologic malignances. However, limited studies were reported to compare the efficacy and safety of CAR-T and donor lymphocyte infusion (DLI) for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after hematopoietic stem cell transplantation (HSCT) comprehensively. We conducted a single-center, retrospective comparative study that consisted of 12 patients who were treated with DLI (control group) and 12 patients treated with donor-derived CD19 CAR-T cells (experimental group, 6 patients also received CD22 or CD123 CAR-T cells sequentially) with 3 overlaps. The event-free survival (EFS) of patients in experimental group was superior to that of the control group: 516 days versus 98 days (p = 0.0415). Compared with 7 of 12 patients treated with DLI suffered grades III–IV acute graft versus host disease (aGVHD), one grade III aGVHD developed in patients treated with CAR-T therapy. No significant difference in the incidence of infection was identified between these two groups. Most patients in the experimental group had only mild cytokine release syndrome and none developed neurotoxicity. The univariate analysis of patients in the experiment group revealed that earlier CAR-T therapy for post-transplantation relapse was associated with better EFS. There was no significant difference in EFS between patients treated with dual-target CAR-T with those with single CD19 CAR-T. In this study, our data supported that donor-derived CAR-T therapy is a safe and potentially effective treatment for relapsed B-ALL after HSCT and may be superior to DLI.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author on reasonable request.
References
Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211–7. https://doi.org/10.1038/leu.2011.351.
Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101. https://doi.org/10.1056/NEJMoa1004383.
Bacigalupo A, Soracco M, Vassallo F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(9):927–32. https://doi.org/10.1038/sj.bmt.1700762.
Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433–44. https://doi.org/10.1200/jco.1997.15.2.433.
Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325–38. https://doi.org/10.1182/bloodadvances.2020001466.
Shah BD, Bishop MR, Oluwole OO, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22. https://doi.org/10.1182/blood.2020009098.
Heng G, Jia J, Li S, et al. Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T Cells in relapsed/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2020;26(7):1606–15. https://doi.org/10.1158/1078-0432.CCR-19-1339.
Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10(1):35. https://doi.org/10.1186/s13045-017-0405-3.
Chen YH, Zhang X, Cheng YF, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020;22(12):755–61. https://doi.org/10.1016/j.jcyt.2020.08.002.
Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671–9. https://doi.org/10.1002/ajh.26160.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.
Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10. https://doi.org/10.1016/j.bbmt.2015.09.001.
Martin PJ, Lee SJ, Przepiorka D, et al. National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. The 2014 clinical trial design working group report. Biol Blood Marrow Transplant. 2015;21(8):1343–59. https://doi.org/10.1016/j.bbmt.2015.05.004.
Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121–30. https://doi.org/10.1182/blood-2017-07-793760.
Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26(5):511–6. https://doi.org/10.1038/sj.bmt.1702555.
Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol. 2008;21(2):205–22. https://doi.org/10.1016/j.beha.2008.02.007.
Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–21. https://doi.org/10.1200/jco.2015.64.5929.
Hua J, Zhang J, Wu X, et al. Allogeneic donor-derived anti-CD19 CAR T cell is a promising therapy for relapsed/refractory B-ALL after allogeneic hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;20(9):610–6. https://doi.org/10.1016/j.clml.2020.04.007.
Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179(4):598–605. https://doi.org/10.1111/bjh.14923.
Wang T, Gao L, Hu X, et al. Chimeric antigen receptor-modified donor lymphocyte infusion improves the survival of acute lymphoblastic leukemia patients with relapsed diseases after allogeneic hematopoietic stem cell transplantation. J Immunother. 2019;42(3):81–8. https://doi.org/10.1097/cji.0000000000000257.
Hua J, Zhang J, Zhang X, et al. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021;56(5):1056–64. https://doi.org/10.1038/s41409-020-01140-6.
Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17. https://doi.org/10.1186/s13045-019-0705-x.
Chen S, Zhang Y, Fang C, et al. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;179:103807. https://doi.org/10.1016/j.critrevonc.2022.103807.
Ghosh A, Smith M, James SE, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23(2):242–9. https://doi.org/10.1038/nm.4258.
Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214–26. https://doi.org/10.1016/j.jcyt.2020.01.015.
Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther. 2021;19(6):749–58. https://doi.org/10.1080/14787210.2021.1855143.
Lombardi A, Saydere A, Ungaro R, et al. Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies. Int J Infect Dis. 2022;120:77–82. https://doi.org/10.1016/j.ijid.2022.04.022.
Yang X, Dai H, Kang L, et al. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019;37(5):655–8. https://doi.org/10.1002/hon.2682.
Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563–70. https://doi.org/10.1038/s41375-020-01056-6.
Yan N, Wang N, Wang G, et al. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2022;24(8):841–9. https://doi.org/10.1016/j.jcyt.2022.01.011.
Acknowledgements
The authors would like to thank all members of the study team, the patients and their families.
Funding
This work was supported by the Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR110105014); the National Natural Science Foundation of China (U2001224); the Science and Technology Program of Guangzhou, China (202201011041); Medical Scientific Research Foundation of Guangdong Province, China (A2021052).
Author information
Authors and Affiliations
Contributions
HX collected data, performed analysis and wrote the manuscript. ZL designed the study and revised the manuscript. SFT and YJH took part in the registration of clinical research. ZL, XZ and JLY contributed to patient management. LJZ contributed to data collection. YHL conceived the project, designed the study and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University (No.2016-XYNK-002, No.2017-XYNK-001).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liang, Z., Xu, H., Zhou, X. et al. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion. Human Cell 36, 1716–1728 (2023). https://doi.org/10.1007/s13577-023-00934-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13577-023-00934-2